LETTERS TO THE EDITOR Turk J Hematol 2018;35:200-216

infiltration and fragility with petechiae and purpura, characteristically affecting the eyelids, beard area, and upper chest [2]. Purpura as the initial manifestation leading to the diagnosis of AL amyloidosis is relatively rare [3,4]. Therefore, cutaneous findings are valuable in making a diagnosis of this challenging disorder since early diagnosis before development of organ failure is essential for improving the prognosis of AL amyloidosis patients.

Keywords: Amyloidosis, Purpura, Congo red

Anahtar Sözcükler: Amiloidoz, Purpura, Kongo kırmızısı

Informed Consent: Informed consent was obtained.

©Copyright 2018 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House **Conflict of Interest:** The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

- 1. Eder L, Bitterman H. Image in clinical medicine. Amyloid purpura. N Engl J Med 2007;356:2406.
- 2. Lachmann HJ, Hawkins PN. Chapter 133. Amyloidosis of the skin. In: Goldsmith LA (ed). Fitzpatrick's Dermatology in General Medicine, 8th edition. New York, McGraw-Hill, 2012.
- Zhao JY, Zhang RN, Duan XH, Xu ZL, Li HW, Gu FS. A case of systemic amyloidosis beginning with purpura. Chin Med J (Engl) 2012;125:555-557.
- McCormick RS, Sloan P, Farr D, Carrozzo M. Oral purpura as the first manifestation of primary systemic amyloidosis. Br J Oral Maxillofac Surg 2016;54:697-699.



Address for Correspondence/Yazışma Adresi: Erman ÖZTÜRK, M.D.. Koç University Hospital, Clinic of Hematology, İstanbul, Turkey

Phone: +90 532 408 95 25

E-mail: ermanozturk@gmail.com ORCID-ID: orcid.org/0000-0002-1559-8047

Received/Gelis tarihi: January 09, 2018 Accepted/Kabul tarihi: March 19, 2018

DOI: 10.4274/tjh.2018.0016

Sclerosing Extramedullary Hematopoietic Tumor

Sklerozan Ekstramedüller Hematopoetik Tümör

♠ Kemal Deniz¹, ♠ Güven Kahriman², ♠ İsmail Koçyiğit³, ♠ Turhan Ökten¹, ♠ Ali Ünal⁴

¹Erciyes University Faculty of Medicine, Department of Pathology, Kayseri, Turkey

²Erciyes University Faculty of Medicine, Department of Radiodiagnostics, Kayseri, Turkey

³Erciyes University Faculty of Medicine, Department of Nephrology, Kayseri, Turkey

⁴Erciyes University Faculty of Medicine, Department of Hematology, Kayseri, Turkey

To the Editor,

Sclerosing extramedullary hematopoietic tumor (SEMHT) is a very rare disease. It was first described by Remstein et al. [1] in 2000 and few cases have been reported since then. It is associated with chronic myeloproliferative disorders. We describe a patient with SEMHT with bilateral renal involvement.

A 72-year-old man was admitted to the emergency clinic with dyspnea and abdominal pain. Physical examination revealed decreased breath sound over the right and left lower lung areas and severe edema in both lower extremities. He was clinically overhydrated. The rest of the physical examination was normal. Routine laboratory tests showed the following: serum levels of hemoglobin, 9.8 g/dL; white blood cell count, 31x109/L; platelet count, 100x109/L; blood urea nitrogen, 36 mg/dL; serum creatinine, 1.9 mg/dL; serum albumin, 2.2 g/dL. The peripheral blood smear was normal. A bone marrow biopsy was not performed. Abdominal ultrasound showed a perirenal

hypoechoic mass compressing the bilateral kidneys (Figure 1a). Magnetic resonance imaging revealed heterogeneous renal capsular involvement with maximum thickness of 30 mm (Figure 1b). Renal Tru-cut biopsies were performed from both kidneys. Microscopically, both lesions showed myxoid and sclerotic stroma intermixed with large atypical cells (Figures 1c and 1d). Immunohistochemistry revealed positivity for factor-8 (Figure 1e) and CD41 in atypical cells (Figure 1f). Scattered mature myeloid cells were positive for myeloperoxidase, while CD34, CD117, S100, CD3, CD30, CD20, glycophorin, MDM2, keratin, EMA, desmin, and myogenin were all negative. The presence of CD41-positive atypical megakaryocytes within the tumor suggested the diagnosis of SEMHT. His previous history of primary myelofibrosis and splenectomy was learned after the histologic diagnosis of the renal tumor.

SEMHT is an uncommon lesion formerly known as fibrous hematopoietic tumor or myelosclerosis [1]. It is associated with

LETTERS TO THE EDITOR Turk J Hematol 2018;35:200-216




Figure 1. a) Abdominal ultrasonographic image and b) magnetic resonance image showing heterogeneous renal capsular mass. c) Photomicrograph showing large atypical megakaryocytes in a myxoid to collagenous background (hematoxylin and eosin, 100°). d) Megakaryocytes at high power view (hematoxylin and eosin, 400x), e) showing factor-8 positivity (400x) and f) CD41 positivity (400^x).

chronic myeloproliferative disorders, mainly chronic idiopathic myelofibrosis in older age groups. SEMHT has a predilection for the mesentery and retroperitoneum. However, tumors involving the skin, liver, kidneys, and lacrimal glands were described as single reports [1,2,3]. SEMHT has usually presented as multiple nodules with varying sizes. Our case showed the diffuse infiltrative nature of the tumor, compressing the bilateral kidneys. Bilateral renal involvement is an unreported radiologic finding. Microscopically, these tumors were characterized by myxoid to sclerotic stroma with thick collagen bundles, intermixed with large atypical megakaryocytes. Occasional foci of mature hematopoietic cells were encountered [1,2]. It is believed that

sclerosis within the tumor was produced by fibroblasts, induced by cytokines released from clonal megakaryocytes. The presence of the JAK2 V617F mutation may also suggest the clonal nature of the lesion [4].

The differential diagnosis includes sclerosing liposarcoma, fibrous histiocytoma/pleomorphic sarcoma. sarcomatoid/anaplastic carcinoma, and Hodgkin lymphoma [1,3]. The presence of dysplastic megakaryocytes with "ink blot-like" nuclei and eosinophilic cytoplasm is in favor of SEMHT. Factor-8, CD41, and CD61 are helpful markers for the confirmation of the diagnosis. Pathologists should keep this rare entity in mind for the differential diagnosis of tumors with anaplastic morphology. High cellular pleomorphism may lead to inaccurate diagnosis of sarcoma or carcinoma and a subsequent unnecessary surgery.

Keywords: Sclerosing extramedullary hematopoietic tumor, Myelofibrosis, Kidney

Anahtar Sözcükler: Sklerozan ekstramedüller hematopoetik tümör, Myelofibrozis, Böbrek

Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

- 1. Remstein ED, Kurtin PJ, Nascimento AG. Sclerosing extramedullary hematopoietic tumor in chronic myeloproliferative disorders. Am J Surg Pathol 2000:24:51-55.
- Kwon Y, Yu E, Huh J, Lee SK, Ro JY. Sclerosing extramedullary hematopoietic tumor involving lesser omentum and ligamentumteres in liver explant. Ann Diagn Pathol 2004;8:227-232.
- 3. Gualco G, Ojopi EB, Chioato L, Cordeiro DL, Negretti F, Bacchi CE. Postsplenectomy sclerosing extramedullary hematopoietic tumor with unexpected good clinical evolution: morphologic, immunohistochemical, and molecular analysis of one case and review of the literature. Appl Immunohistochem Mol Morphol 2010;18:291-295.
- 4. LeBlanc RE, Lester L, Kwong B, Rieger KE. JAK2-positive cutaneous myelofibrosis presenting as sclerosing extramedullary hematopoietic tumors on the scalp: case presentation and review of the literature. J Cutan Pathol 2015;42:858-862.

©Copyright 2018 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House



Address for Correspondence/Yazışma Adresi: Kemal DENİZ, M.D., Erciyes University Faculty of Medicine, Department of Pathology, Kayseri, Turkey

Phone: +90 532 492 22 38

E-mail: drkdeniz@yahoo.com ORCID-ID: orcid.org/0000-0001-7749-2152

Received/Geliş tarihi: December 06, 2017 Accepted/Kabul tarihi: January 30, 2018

DOI: 10.4274/tjh.2017.0438